Sugg Sonia L, Krzywda Elizabeth A, Demeure Michael J, Wilson Stuart D
Division of Pancreatobiliary/Endocrine Surgery, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.
Surgery. 2004 Dec;136(6):1303-9. doi: 10.1016/j.surg.2004.06.062.
A focused surgical approach for primary hyperparathyroidism relies on the ability of preoperative imaging and intraoperative parathyroid hormone monitoring (IOPTH) to detect multiple gland disease (MGD). The study objective was to determine the best predictor for MGD.
First time parathyroidectomy was performed on 233 patients with primary hyperparathyroidism who underwent preoperative sestamibi imaging, ultrasound, and IOPTH between December 1999 and January 2004.
Single gland disease (SGD) was found in 204 (88%) and MGD in 23 (10%) patients. Hyperparathyroidism persisted in 6 of 233 patients (2.6%). For patients with MGD, sestamibi imaging correctly predicted MGD in 2 of 23 (9%) patients, incorrectly showed SGD in 9 of 23 (39%), and was negative in 12 of 23 (52%). Ultrasound correctly predicted MGD in 6 of 23 (26%) patients, incorrectly predicted SGD in 6 of 23 (39%), and was negative in 8 of 23 (35%). Together sestamibi imaging and ultrasound predicted MGD in 7 of 23 (30%) patients, incorrectly predicted SGD in 7 of 23 (30%), was negative in 7 of 23 (30%), and was discordant in 10 of 23 (5%). IOPTH indicated MGD in 15 of 18 (83%) patients but falsely predicted cure after single gland excision in 3 of 18 (17%). The combination of sestamibi imaging, ultrasound, and IOPTH detected MGD in 16 of 18 (89%) patients.
Ultrasound was more sensitive for detecting MGD than sestamibi imaging. Ultrasound and sestamibi imaging together provided information warranting a bilateral approach in 70% of patients with MGD. IOPTH was the most sensitive for MGD, but combining all 3 tests was the best predictor, identifying the majority of patients with MGD.
原发性甲状旁腺功能亢进的针对性手术方法依赖于术前成像和术中甲状旁腺激素监测(IOPTH)检测多腺体疾病(MGD)的能力。本研究目的是确定MGD的最佳预测指标。
对1999年12月至2004年1月期间接受术前锝-99m甲氧基异丁基异腈(sestamibi)成像、超声检查和IOPTH的233例原发性甲状旁腺功能亢进患者首次进行甲状旁腺切除术。
204例(88%)患者为单腺体疾病(SGD),23例(10%)患者为MGD。233例患者中有6例(2.6%)甲状旁腺功能亢进持续存在。对于MGD患者,sestamibi成像在23例患者中的2例(9%)正确预测了MGD,在23例患者中的9例(39%)错误显示为SGD,在23例患者中的12例(52%)为阴性。超声在23例患者中的6例(26%)正确预测了MGD,在23例患者中的6例(39%)错误预测为SGD,在23例患者中的8例(35%)为阴性。sestamibi成像和超声联合在23例患者中的7例(30%)预测了MGD,在23例患者中的7例(30%)错误预测为SGD,在23例患者中的7例(30%)为阴性,在23例患者中的10例(5%)结果不一致。IOPTH在18例患者中的15例(83%)提示MGD,但在18例患者中的3例(17%)错误预测单腺体切除后治愈。sestamibi成像、超声和IOPTH联合检测出18例患者中的16例(89%)为MGD。
超声检测MGD比sestamibi成像更敏感。超声和sestamibi成像联合可为70%的MGD患者提供双侧手术的依据。IOPTH对MGD最敏感,但三项检查联合是最佳预测指标,可识别大多数MGD患者。